Amedisys — Q2 2022 Earnings Presentation
18 slides from Amedisys's earnings presentation, Jul 27, 2022
Slide 1: Amedisys Second Quarter 2022 Earnings Call Supplemental Slides
1 Amedisys Second Quarter 2022 Earnings Call Supplemental Slides July 28th, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c
Slide 3: Our Key Areas of Focus
3 Our Key Areas of Focus Strategic areas of focus and progress made during Q2’22 • Home Health*: Total same store admissions flat • Hospice: Total same store admissions +6%, ADC flat; +2.5% sequentially • Personal Care: PC Network drove ~$406K in revenue to Home Health and Hospice via care coordinat
Slide 4: Highlights and Summary Financial Results (Adjusted): 2Q 22
4 Highlights and Summary Financial Results (Adjusted): 2Q 2022(1) Home Health total same store admissions flat; Hospice same store admissions +6%; EBITDA margin decline driven by the addition of Contessa, labor costs and the return of sequestration 1. The financial results for the three-month period
Slide 5: Revenue mix by segment and payor
5 66.1%13.2% 20.7% Home Health Revenue Medicare FFS Private Episodic Per Visit 61.6% 35.0% 2.6% 0.8% Amedisys Consolidated Revenue Home Health Hospice Personal Care High Acuity Care • Medicare FFS: Reimbursed over a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us o
Slide 6: Home Health and Hospice Segment (Adjusted) – 2Q 2022
6 Home Health and Hospice Segment (Adjusted) – 2Q 2022(1) • Revenue per Episode up 2.1% (primarily due to +3.2% rate increase effective 1/1/2022 partially offset by the reinstatement of sequestration at 1%) • Y/Y Total CPV up $6.77 (+6.8%, primarily due to planned wage increases, wage inflation, sig
Slide 7: General & Administrative Expenses – Adjusted
7 2Q21 3Q21 4Q21 1Q22 2Q22 Salary and Benefits 22.0 22.1 21.7 23.8 23.3 Other 11.6 12.8 10.4 10.2 6.7 Corp. G&A Subtotal 33.6 34.9 32.1 34.0 30.1 Non-cash comp 4.5 2.8 4.0 1.6 2.6 Adjusted Corporate G&A 38.1 37.7 36.1 35.6 32.7 $ in Millions 2Q21 3Q21 4Q21 1Q22 2Q22 Home Health Segment - Total 81.3
Slide 8: Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted
8 Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by labor cost pressures and lower visits *Note: Direct comparison with industry competitors CPV calculation $25.00 $50.00 $75.00 $100.00 2Q21 1Q22 2Q22 Cost Per Visit (CPV) Salaries Contractors Benefits Transp
Slide 9: Driving Top Line Growth
9 Driving Top Line Growth Home Health total volume and Personal Care billable hours lagging due to prolonged COVID-19 impacts (lower utilization and staffing challenges). Hospice volume metrics continue to improve as both admissions and average daily census were the highest for the periods presented
Slide 10: Industry Leading Quality Scores
10 Industry Leading Quality Scores Metric JAN 22 Release APR 22 Release Jul 22 Preview Oct 22 Preview Quality of Patient Care 4.33 4.38 4.46 4.49 Entities at 4+ Stars 92% 97% 99% 100% Metric OCT 20 Release JAN 22 Release APR 22 Release Jul 22 Preview Patient Satisfaction Star 4.28 3.61 3.73 3.92 Per
Slide 11: Hospice Quality: Moving Towards Best-in-Class Hospice Quality
11 Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Notes: Included in the above analysis are active care centers. HIS data includes all active care centers. CAHPS excludes Asana, AseraCare, and CCH acquisitions as they were acquired after the start of the re
Slide 12: Debt and Liquidity Metrics
12 Debt and Liquidity Metrics Net leverage ~1.5x 1. Net debt defined as total debt outstanding ($459.0M) less cash ($48.8M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($277.8M). 3. Liquidity defined as the sum of cash balance and available revolving
Slide 13: Cash Flow Statement Highlights
13 Cash Flow Statement Highlights (1) Q2 cash flow statement reflects two home health acquisitions and the buyback of 150,000 shares during the quarter. The second half of the COVID-19 relief payroll tax deferral ($27M) is due in December 2022. 1. Free cash flow defined as cash flow from operations
Slide 14: Income Statement Adjustments
14 Income Statement Adjustments (1) 1. The financial results for the three-month periods ended June 30, 2021, September 30, 2021, December 31, 2021, March 31, 2022 and June 30, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GA
Slide 15: 2022 Guidance
15 2022 Guidance
Slide 16: Amedisys 2022 Updated Guidance
16 Amedisys 2022 Updated Guidance Revenue (updated); EBITDA and EPS (maintained) ($M except for EPS) Original Guidance Updated Guidance Adjusted Revenue $2,330 - $2,365 $2,290 - $2,310 Adjusted EBITDA $275 - $285 $275 - $285 Adjusted EPS $5.23 - $5.45 $5.23 - $5.45 Guidance Disclaimer COVID-19 has i
Slide 17: Environmental, Social, Governance (E.S.G.) Considerations
17 Environmental, Social, Governance (E.S.G.) Considerations
Slide 18: Environmental, Social, Governance (E.S.G.) Considerations
18 Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physic